Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant novel coronavirus B.1.1.529 variant vaccine (adenovirus type 5 vector) for inhalation
- Development stage
- Unknown
- Lead developer
- CanSino Biologics
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Inhalation
01
Overview
This vaccine is an inhaled, recombinant adenovirus type 5 (Ad5) vectored formulation specifically engineered to target the B.1.1.529 (Omicron) variant of SARS-CoV-2. Developed by CanSino Biologics in collaboration with institutions such as the Chongqing Center for Disease Control and Prevention, the vaccine utilizes a replication-deficient Ad5 platform to deliver the genetic sequence of the Omicron spike protein. Unlike traditional intramuscular injections, this formulation is administered via oral inhalation using a nebulizer, which is designed to trigger mucosal immunity in the respiratory tract (including secretory IgA) in addition to systemic humoral and cellular immune responses. It is primarily being investigated as a booster dose to enhance protection against variant-driven breakthrough infections in individuals who have completed a primary vaccination series.
- Other names
- Inhaled Ad5-vectored Omicron variant COVID-19 vaccineInhaled Ad5-nCoV Omicronrecombinant novel coronavirus B.1.1.529 variant vaccine (adenovirus type 5 vector) for inhalation
02
Targets
NeuraminidaseCXADR (Coxsackievirus and adenovirus receptor)Severe acute respiratory syndrome coronavirus 2 spike glycoprotein (Omicron B.1.1.529)
Beyond the preview
Go deeper on recombinant novel coronavirus B.1.1.529 variant vaccine (adenovirus type 5 vector) for inhalation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant novel coronavirus B.1.1.529 variant vaccine (adenovirus type 5 vector) for inhalation.